Acquisition Of Prostiva Radio Frequency Therapy

3 Months Ended

Sep. 30, 2011

Acquisition Of Prostiva Radio Frequency Therapy

Acquisition Of Prostiva Radio Frequency Therapy

4.         Acquisition of Prostiva Radio Frequency Therapy

On September 6, 2011, The Company entered into agreements with Medtronic, Inc. relating to the Prostiva® Radio Frequency (RF) Therapy System, a minimally invasive medical product for the treatment of BPH.  As a result of those agreements, the Company obtained an exclusive, worldwide license to the Prostiva technology for a ten year term, with an option to purchase the technology anytime during the ten year term for a maximum purchase price of $10 million. 

The above transaction was accounted for as a business combination.    Under the terms of the agreements the Company will be responsible for the manufacturing, sourcing, operations, compliance, quality, regulatory and other matters of the Prostiva RF Therapy System.   The Company entered into this transaction to increase our customer base, sales force, and addressable patient population and expand Urologix's position as the leading provider of in-office treatment solutions for BPH with over 50 percent market share.

The Company hired independent valuation specialists to assist management with our determination of the fair value of the consideration to be paid as well as the fair value of the assets acquired in the acquisition of the Prostiva RF Thereapy System.Management is responsible for the estimates and valuations.The work performed by the independent valuation specialists has been considered in management's estimates of fair value reflected below.

The Company estimates that the fair value of the consideration to be paid to acquire the Prostiva business is approximately $7.2 million, of which approximately $6.7 million is still payable.Included in the total consideration is the licensing fee, of which $500,000 was paid on September 6, 2011 and $500,000 is due on the anniversary of this date, deferred payments for acquired inventory, and royalties on Prostiva products sold, subject to minimum and maximum amounts.The consideration consists of non-contingent future cash payments with an acquisition date fair value of $4.3 million. The estimated royalty payments between the minimum and maximum amounts are contingent consideration and are measured at fair value at the acquisition date by applying an appropriate discount rate that reflects the risk factors associated with the payment streams.The Company estimates the fair value of the future contingent consideration at $2.9 million.The contingent consideration will be remeasured to fair value at each reporting date until the contingency is resolved with the changes in fair value recognized in operating income/(loss).

We assumed no liabilities in the acquisition.The allocation of purchase consideration to assets acquired is not yet finalized as we continue to evaluate the fair value of certain assets related to the acquisition of Prostiva.The preliminary fair values of the assets acquired by major class in the acquisition are as follows (in thousands):

Finished Goods Inventory	$1,362
Manufacturing Equipment	128
Identifiable Intangible Assets Patents and Technology	1,529
Customer List	531
Trademarks	325
Goodwill	3,307
Total assets acquired	$7,182

Additional information which existed at the acquisition date but was at that time unknown to the Company may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. Changes to amounts recorded as assets may result in a corresponding adjustment to goodwill.

The preliminary goodwill of $3.3 million is primarily attributable to the future expected revenue growth as a result of increased market penetration and an expanded sales force, as well as from an assembled workforce obtained in the acquisition.  The Company has not yet determined whether goodwill and intangibles will be deductible for tax purposes.    

The patents and technology intangible assets consist of patents and technology, many of which are used in the Prostiva RF Therapy System. Trademarks consist of the use of the Prostiva name in the BPH marketplace. The Company used a relief from royalty method to determine the estimated fair values of the patents and technology and trademark intangible assets. The relief from royalty method applies a cost-savings concept under the notion that if Urologix did not own the asset it would pay a royalty to a third party for the right to use that asset. The fair value of the patents and technology and trademarks are based on the present value of the royalty payments saved by owning the asset, based on an appropriate market participant royalty rate. Revenue on which the royalty was calculated was projected over the expected remaining useful life of the core patents and technology and trademarks.

The Company used a Multi-Period Excess Cash Flow model under the income approach to determine the fair value of the customer list. The Multi-Period Excess Cash Flow model projects future cash flows based on management's estimates and assumptions, including a historical attrition rate, that will be derived from the sale of products to existing Prostiva customers, adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow steam.

For the three-month periods ended September 30, 2011, we incurred $120,000 of transaction related expenses, primarily related to legal and accounting fees, which are included in selling, general and administrative expenses. Total cumulative transaction expenses were $223,000, of which $103,000 were incurred in prior periods and included in selling, general and administrative expenses in those periods.

In addition to the above transaction payments, we are required to pay an annual licensing fee of $65,000 to Medtronic, as well as a monthly $30,000 transition services fee beginning in November 2011 for transition services to be provided by Medtronic until the earlier of the end of the initial term of the Transition Agreement or the last of certain United States or European Union regulatory transfers. As these fees are for services being provided by Medtronic on a go forward basis, they are not included in total consideration for the acquisition of the Prostiva RF Therapy System and will be expensed in the period incurred and reported as part of selling, general and administrative expenses.

The revenue and operating expenses related to the Prostiva business have been included in our results of operations since September 6, 2011, the date of acquisition. The acquired Prostiva business was not operated as a separate subsidiary, division or entity by Medtronic, Inc. As a result, we are unable to accurately determine earnings/(loss) for the Prostiva business on a standalone basis since the date of acquisition. Prostiva revenue included in reported Urologix revenue for the three-month period ended September 30, 2011 totaled approximately $430,000.

As previously mentioned, as the Prostiva business was not operated as a separate subsidiary, division or entity, Medtronic did not maintain separate financial statements for the Prostiva business.  As a result, the following unaudited pro-forma financial information represents revenue and only direct expenses for the Prostiva business prior to the September 6, 2011 acquisition date.  The below pro-forma financial information shows the revenue and net income/(loss) as if the businesses were combined for the three-month periods ended September 30^th  (in thousands except per share amounts).   

	Three months ended
	September 30,
	2011	2010
Pro forma net revenue	$4,398	$6,021
Pro forma net income/(loss)	($ 1,221)	($299)
Pro forma net income/(loss) per share (basic)	($0.08)	($0.02)
Pro forma net income/(loss) per share (diluted)	($0.08)	($0.02)

The above pro forma financial information excludes the non-recurring acquisition related expenses of $120,000. The above pro forma financial information does include however the amortization and depreciation expense from acquired Prostiva assets, the implied interest expense on deferred acquisition payments, and the expense related to the increase in the fair value of acquired Prostiva inventories as if they had occurred as of July 1st of the respective periods. The pro forma financial information is not indicative of the results that would have actually been obtained if the acquisitions had occurred as of the beginning of fiscal years 2012 or 2011, or of results that may be obtained in the future.